Abstract
Opioid use disorder (OUD) is a major public health threat, contributing to morbidity and mortality from addiction, overdose, and related medical conditions. Despite our increasing knowledge about the pathophysiology and existing medical treatments of OUD, it has remained a relapsing and remitting disorder for decades, with rising deaths from overdoses, rather than declining. The COVID-19 pandemic has accelerated the increase in overall substance use and interrupted access to treatment. If increased naloxone access, more buprenorphine prescribers, greater access to treatment, enhanced reimbursement, less stigma and various harm reduction strategies were effective for OUD, overdose deaths would not be at an all-time high. Different prevention and treatment approaches are needed to reverse the concerning trend in OUD. This article will review the recent trends and limitations on existing medications for OUD and briefly review novel approaches to treatment that have the potential to be more durable and effective than existing medications. The focus will be on promising interventional treatments, psychedelics, neuroimmune, neutraceutical, and electromagnetic therapies. At different phases of investigation and FDA approval, these novel approaches have the potential to not just reduce overdoses and deaths, but attenuate OUD, as well as address existing comorbid disorders.
Introduction
Opioid use disorder (OUD) is a complex physical and emotional disease with important mood and anhedonic impacts. It also contributes to comorbid medical and infectious diseases that require evaluation and treatment (1). Drug use changes the brain, behavior, and motivational hierarchy via induction of neuroplasticity; the patient with OUD acquires a chronic, progressive neurodysregulation that shortens life, reduces career opportunities and earning potential, increases the risks of other diseases, and often ends in death. Fentanyl is becoming increasingly common. Fentanyl is highly effective at producing OUD and contributing to anhedonia and overdose. Many with OUD also use methamphetamine and cocaine for their euphoric mood effects, but when used regularly, these drugs can lead to alterations in brain function to trigger negative effects, such as dysphoria, anhedonia, and depression (2). Unfortunately, polysubstance use and relapses are the norm rather than the exception (3, 4). OUD is part of the substance use disorder (SUD) spectrum but is unique among other SUDs in that there is a solid understanding of its neurobiology and there are Food and Drug Administration (FDA) approved treatments (5). Medical management of OUD has not changed much since the 1970s, with agonists like methadone and antagonists like naltrexone. The addition of the partial agonist buprenorphine and extended-release naltrexone (XR-NTX) were important milestones.
Opioid use in the context of worsening substance use
Substance use disorder (SUD) is one of the nation’s most pressing public health challenges. According to the 2021 World Drug Report by the United Nations Office on Drugs and Crime (UNODC), at least 275 million people worldwide used controlled substances in the previous year, with more than 36 million meeting the criteria for a substance use disorder (6). Among controlled substances contributing to the burden of disease, opioids stand out as the primary driver of drug-related fatalities, comprising 69% of deaths directly associated with drug use.
Recent data show the evidence-based and FDA-approved treatments for OUD reduce stigma and improve treatment access. Although more people are currently being treated with medications for opioid use disorder (MOUD), deaths continue to increase. Nationally, over the past 15 years, at least 500,000 deaths have been attributed to opioid overdoses, contributing to the decrease in US life expectancy. This concerning trend has worsened during the COVID-19 pandemic (7, 8). Those with SUDs are highly dependent on traditional in-person and often emergent care (9). However, pandemic policies--such as the quarantine--to save lives from the COVID-19 virus, have led to disruptions in such care, leading to worsening opioid overdoses and deaths during the lockdown (10, 11). The Centers for Disease Control and Prevention estimated that for the first time ever, over 100,000 deaths occurred due to overdoses during a 12-month period, and the current Director of the Office of National Drug Control Policy suggested that annual opioid-induced deaths could reach 165,000 by 2025 (12).
By necessity, the opioid crisis has shifted the focus to addressing overdose deaths rather than treatment and recovery. A considerable proportion of opioid overdose fatalities are now linked to synthetic opioids, particularly fentanyl. The opioid epidemic has transitioned from being primarily of prescription opioids to heroin and now subsequently fentanyl. Concerningly, with the increase in synthetic opioid use, the trend shows that more and more individuals are also consuming other substances, sometimes inadvertently from contamination and others from co-ingestion of other prescription or psychostimulant drugs. Although SUDs are often discussed in isolation, the reality is that many individuals are combining multiple drugs, often in fatal combinations. For example, in more than half of all methamphetamine-related deaths and about three-quarters of all cocaine-related deaths in 2019, there were co-ingestion of opioids (7). Illicitly manufactured fentanyl is implicated in the increase in overdose deaths in cocaine use, and co-ingestion of fentanyl and other substances, such as methamphetamine, cocaine, and ecstasy, have been shown in postmortem examinations of overdose deaths (13, 14). Patients in the psychiatric emergency rooms often test positive for fentanyl while testing positive for other psychostimulants; unknown contamination with fentanyl puts opioid-naïve psychostimulant users at an increased risk of overdose (15, 16). While the public attention remains on opioid-related deaths, a concerning upsurge in fatalities linked to stimulant drugs suggests that the opioid crisis may be entering a new phase. The ongoing substance use crisis is constantly evolving, marked by changing patterns of substance use and availability, as well as concurrent use of multiple drugs across drug classes.
OUD overdose reversal starts with naloxone
Among all potential interventions, increasing the access to naloxone would have the most significant effect in reducing opioid-use related deaths, according to Pitt et al. (17). While important to implement other strategies, no other harm reduction approach has had as significant of an impact. Naloxone is classified as a “pure” antagonist, meaning it lacks opioid agonistic traits seen in other opioid antagonists, and it displaces other full and/or partial opioid agonists that engage opioid receptors to reverse the effects of euphoria, analgesia, as well as respiratory depression, sedation, and bradycardia. Naloxone is a rapid-acting, easy-to-administer agent that can be given in the setting of opioid intoxication and overdose, to provide swift, life-saving reversal (18). Within minutes, naloxone can fully reverse the effects of opioids. Regardless of the substance use history, naloxone offers substantial potential benefits and minimal risk when overdose is suspected. Thus, the importance of promoting access to naloxone in those who use opioids as well as in potential bystanders who can intervene in an overdose setting cannot be understated. However, it is also important to note that naloxone serves as an intervention rather than a remedy for the underlying condition. Naloxone can treat the overdose acutely, but it does not treat the OUD. Existing evidence does not indicate that experiencing an overdose and subsequent reversal with naloxone alters the trajectory of those with OUD; patients must be connected to subsequent treatment services that include MOUDs for improved outcomes (1). Thus, access to both is critical to reduce OUD related deaths.
Transition with urgency: from overdose reversal to treatment of the whole patient with OUD
It is difficult to accurately estimate the total economic burden associated with substance use, encompassing factors from the cost of treatment as well as reduced productivity, loss of life, and the emotional toll on those left behind (19). Although it has been suggested that mortality can be reduced by evidenced-based treatment approaches, OUD is characterized by a chronic and relapsing course—initially driven by activation of the brain’s reward system, but later increasingly dominated by anti-reward neural circuits that trigger negative emotional states and relapses (3, 20). It is noteworthy that one important anti-reward neurocircuit phenomena is the subsequent opioid-induced reduction of functional connectivity (21).
No single treatment approach has proven to be universally effective, as many have other medical and psychiatric comorbidities that often hinder successful treatment. Furthermore, racial and economic disparities in morbidity and mortality point to inequalities that must be addressed and rectified (22). Even harm reduction strategy of naloxone is a limited strategy in that it often requires someone else other than the patient to help administer the reversal agent (23).
The current mainstay of treatment for OUD is MOUDs. Buprenorphine, extended-release naltrexone (XR-NTX), and methadone are all FDA-approved and have been shown to be effective in reducing the number of overdoses in those who remain adherent to treatment—which remains a challenge in access and retention (24–26). Buprenorphine is the most prescribed of the MOUDs and it may help mitigate anhedonia and withdrawal symptoms associated with fentanyl use (27, 28). However, treatment dropouts are common, and patients are often re-initiated on the same buprenorphine (29). Once an overdose is reversed, the patient remains at high risk for overdose, which has led to initiation of buprenorphine in hospitals, emergency rooms, and immediately after rescue. This has not decreased the overall number of deaths, but provides another opportunity to successfully treat the patient.
XR-NTX is a monthly injectable opioid antagonist that acts to block other opioids from activating receptors. Despite the monthly injectable formulation of the drug, transition and compliance to treatment remain an issue, as patients need to go through detoxification to start the medication. Therefore, despite similar efficacy of XR-NTX to buprenorphine shown in the XBOT trial, buprenorphine is more often initiated (30). Augmentation of naltrexone therapy with other agents such as clonidine, lofexidine, and buprenorphine are often tried in outpatient detoxification settings. With augmentation of non-opioid agents like clonidine, patients are able to successful initiate and maintain an opioid antagonist, rather than a partial agonist. This is particularly important for those in occupations related to public for whom methadone or buprenorphine is not prescribed and for those who may be mandated to treatment for their OUD (26, 31).
While MOUDs are highly effective and FDA approved, they are not a “magic bullet”, and the entire scientific community should continue their pursuit to develop alternative non-addictive and safe treatments (32, 33). Despite best efforts, the existing strategies for preventing and treating OUD will still result in more than 700,000 deaths in the US between 2016 and 2025, from both prescription and non-prescription opioids such as fentanyl (34).
The most favorable outcomes are associated with extended duration of MOUD therapy. However, treatment drop out and relapses are common. When OUD treatment with a MOUD ends or is discontinued by the patient, they often relapse, overdose, and rarely have the disease remitted. Risk of overdose appears to persist even after completion of buprenorphine treatment, and stopping MOUD is associated with an elevated overdose risk, raising a controversial question about whether opioid agonist treatment can lead to opioid deficiency or opioid system dysregulation (3, 35). This risk of relapse and overdose persists even several years of recovery; thus, recovery can be akin to a “remission” of OUD symptoms rather than a complete cure or elimination. While it may be true that prolonged MOUD is the most effective in preventing relapse, it is also true that the quality of life on MOUD treatment can be negatively impacted and most patients do not remain on lifelong treatment for OUD. One study revealed that patients on long-term Suboxone exhibited significantly flat affect (p < 0.01) and reported diminished sense of feelings of happiness, sadness, and anxiety compared to both the general population and Alcoholics Anonymous (AA) groups (36). Despite the limitations, treatment of OUD is still linked to improved outcomes in morbidity and mortality, and integration of MOUD with effective, evidence-based therapy and contingency management lead to enhanced outcomes (37). It is thought that achieving successful treatment of OUD requires not just medications but a comprehensive approach that addresses the psychosocial factors that predispose and perpetuate individuals toward opioid use disorder.
Brain and behavioral recovery take hope, patience, time, and effort. No one knows if or when the brain will return to its pre-morbid function. Interestingly, research from China revealed that even after 10 months of heroin abstinence, there were changes in resting state of functional connectivity (RSFC) patterns between the midbrain and various cortical regions, such as diminished RSFC of the medial orbitofrontal cortex (mOFC) and anterior cingulate cortex compared to non-heroin using controls. Persistent reward circuitry abnormalities were present after 16 months, but enhancement of RSFC in certain circuits were seen in long-term abstinence compared with short-term (38, 39). Abstinence from substance use, as well as adopting a healthy diet, and other regenerative treatments, including exercise and transcranial magnetic stimulation may all help expedite brain recovery (40, 41).
Pro-dopamine regulation and assessment of preaddiction
At the population health level, a “preaddiction” model, like prediabetes, has been suggested to ring the alarm bell for an early intervention before the addiction progresses to cause more severe symptoms and engender chronic changes in the brain’s neural circuitry. SUD is currently defined by the DSM-5 based on 11 symptoms of impaired control, and severity is determined by the number of symptoms patients endorse. The term addiction specifically refers to severe SUD, which is defined as having six or more symptoms. This occurs in about 4–5% of adults, compared to 13% of the adult population who have mild to moderate SUD, defined as having 2–5 symptoms (42). Although larger proportion of the population suffer from mild to moderate SUD, public health policies and treatment focus on those with severe, often chronic addictions, to prevent overdoses and deaths, rather than the much larger population grappling with early-stage SUDs. By focusing on those with early-stage addiction, McLellan et al. argue that a preaddiction model that looks for early signs of addiction increases public awareness and allows early intervention that can increase disease detection, shorten delays to treatment, and prevent progression (42, 43). Directors of the National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism have also advocated for the integration of “preaddiction” to the conceptualization of addiction in the DSM.
Although the term preaddiction borrows from the advances made in diabetes, but it is best conceptualized as dopamine or reward dysregulation, where there is a net hypodopaminergia within the meso-limbic reward circuitry from inappropriate or dysregulated neurotransmitter systems (44, 45). Therefore, the terms “reward deficiency” or “reward dysregulation” have also been proposed (46, 47). Reward deficiency syndrome (RDS) refers to behavioral dysfunctions resulting from the disruption of the reward circuitry, due to both genetic and epigenetic factors, and can describe a wide spectrum of psychiatric disorders, from various addictions to obsessive and compulsive disorders and other behavioral conditions (47).
Ways to improve on existing treatment approaches
Public health solutions proposed to address the worsening opioid epidemic include: relaxing the restrictions for physicians to be able to prescribe MOUD; increasing insurance coverage to increase access to treatment for patients (48–51); inducting patients on high-dose buprenorphine in the emergency department (52, 53); and implementing contingency management along with medical treatment to address other key issues of patients undergoing treatment, such as other concurrent substance use (50). Widespread adoption of these practices may help improve treatment retention and reduce overdoses and deaths, to address critical gaps in delivery of existing treatments (37, 54–56).
All these measures would be helpful to curb damage of the OUD at the population level, but still does not address the intrinsic limitations of existing treatments. Limited effectiveness of existing pharmacologic treatments and harm reduction approaches leaves a desire for more durable, novel treatment approaches especially as they relate to the required induction of “dopamine homeostasis” (57–59).
Novel treatments for SUDs are being investigated, most notably interventional neuromodulatory interventions such as transcranial magnetic stimulation (TMS) and deep brain stimulation (DBS), as well as psychedelics and neuroimmune therapies. Rather than working at modulating specific opioid receptors as existing MOUDs do, these proposed treatments target other aspects of substance use pathophysiology, such as the mesolimbic neural circuitry modulating reward and dorsolateral prefrontal and orbitofrontal cortex involved in craving, or the neuroimmune and epigenetic modulations that occur in response to substances (60, 61).
Developments in interventional neuromodulation treatments for OUD
Interventional neuromodulational treatments such as TMS and DBS work by modulating neural circuits and synaptic plasticity, and several neuromodulating modalities have been investigated for use in various neurologic and psychiatric conditions (62). TMS is a noninvasive treatment that utilizes an extracranial magnetic coil to induce a magnetic field that can stimulate or inhibit targeted cortical and subcortical structures. It is currently FDA-approved for treatment of psychiatric conditions including major depressive disorder and obsessive-compulsive disorder. Clinical trials have shown its effectiveness in reducing substance craving via targeting of the dorsolateral prefrontal cortex, with effects on curbing substance use lasting greater than the immediate treatment period, with various substances such as cocaine, methamphetamine, alcohol, heroin, and cigarette use (63–70). A meta-analysis of repetitive TMS (rTMS) on addiction has found a small, persistent effect on stimulant and behavioral addiction, but not on depressants such as alcohol, opioids, and cannabis (71). However, currently multiple randomized controlled trials are being conducted for various TMS protocols to treat patients with opioid use as well as uncover mechanisms (72–83). Further understanding of the exact mechanism and optimization is needed to implement TMS as treatment for OUD (84). One important aspect regarding TMS relates to the concept of utilizing QEEG to determine individualized or personalized signatures termed PRTMS, first coined and developed by Kevin T. Murphy (85).
Similarly, DBS is a neuromodulatory treatment method that can directly stimulate targeted brain regions, but unlike TMS, it typically relies on surgically implanted electrodes. It has FDA approval for various neurologic conditions, such as Parkinson’s disease, tremors, dystonia, as well as epilepsy and OCD. With its ability to reach deeper subcortical structures, DBS is also being investigated for other psychiatric conditions, such as treatment-resistant depression, pain, multiple sclerosis, and addiction. Specifically for addiction, animal models have shown that modulation of nucleus accumbens (NAc) can reverse synaptic changes from cocaine and alcohol use (60, 62), and small case studies in humans have shown effectiveness in treating alcohol use and heroin use (86). More registered clinical trials are examining DBS’s effect in various substance use, including both randomized and non-randomized clinical trials on DBS of NAc of the mesolimbic system as well as DBS specifically for the treatment for severe OUD (87–94).
Beyond TMS and DBS, other similar modalities such as vagus nerve stimulation (VNS), focused ultrasound (FUS), and transcranial direct current stimulation (tDCS) are being investigated, with varying degrees of invasiveness and spatial resolution. VNS is FDA-approved for treatment-resistant depression and epilepsy, and FUS is approved for use in treatment-resistant Parkinson’s disease as well as essential tremor (95, 96), while tDCS does not have any FDA-approved indications. A small randomized clinical trial on transcutaneous VNS has found significant improvement in behavioral and physiologic opioid withdrawal symptoms, indicating potential utility as adjunct treatment for OUD (93). Although not FDA-approved, tDCS has some evidence for utility in depression and addiction, and multiple clinical trials are ongoing for its use in neuropsychiatric conditions (81, 97–101). FUS is also being investigated in a small, open-label clinical trial for feasibility in treatment for OUD (102).
Overall, more evidence is needed before neuromodulatory modalities are adopted in OUD treatment, but the strength of these proposed therapies is that they work via modulating neural circuitries and synaptic plasticity, rather than maintaining patients on opioid maintenance treatments, as well as treat other comorbid neuropsychiatric conditions, such as other SUDs and mood disorders.
Renewed interest in psychedelics for SUD
Psychedelic medicine has seen a resurgence of interest in recent years as potential therapeutics, including for SUDs (103, 104). Prior to the passage of the Controlled Substance Act of 1970, psychedelics had been studied and utilized as potential therapeutic adjuncts, with anecdotal evidence and small clinical trials showing positive impact on mood and decreased substance use, with effect appearing to last longer than the duration of use. Many psychedelic agents are derivatives of natural substances that had traditional medicinal and spiritual uses, and they are generally considered to have low potential for dependence and low risk of serious adverse effects, even at high doses. Classic psychedelics are agents that have serotonergic activity via 5-hydroxytryptamine 2A receptors, whereas non-classic agents have lesser-known neuropharmacology. But overall, psychedelic agents appear to increase neuroplasticity, demonstrating increased synapses in key brain areas involved in emotion processing and social cognition (105–109). Being classified as schedule I controlled substances had hindered subsequent research on psychedelics, until the need for better treatments of psychiatric conditions such as treatment resistant mood, anxiety, and SUDs led to renewed interest in these agents.
Of the psychedelic agents, only esketamine—the S enantiomer of ketamine, an anesthetic that acts as an NMDA receptor antagonist—currently has FDA approval for use in treatment-resistant depression, with durable effects on depression symptoms, including suicidality (110, 111). Ketamine enhances connections between the brain regions involved in dopamine production and regulation, which may help explain its antidepressant effects (112). Interests in ketamine for other uses are expanding, and ketamine is currently being investigated with plans for a phase 3 clinical trial for use in alcohol use disorder after a phase 2 trial showed on average 86% of days abstinent in the 6 months after treatment, compared to 2% before the trial (113).
Psilocybin, an active ingredient in mushrooms, and MDMA, a synthetic drug also known as ecstasy, are also next in the pipelines for FDA approval, with mounting evidence in phase 2 clinical trials leading to phase 3 trials. Psilocybin completed its largest randomized controlled trial on treatment-resistant depression to date, with phase 2 study evidence showing about 36% of patients with improved depression symptoms by at least 50% at 3 weeks and 24% experiencing sustained effect at 3 months after treatment, compared to control (114). Currently, a phase 3 trial for psilocybin for cancer-associated anxiety, depression, and distress is planned (115). Similar to psilocybin, MDMA has shown promising results for treating neuropsychiatric disorders in phase 2 trials (116), and in 2021, a phase 3 trial showed that MDMA-assisted therapy led to significant reduction in severe PTSD symptoms, even when patients had comorbidities such as SUDs; 88% of patients saw more than 50% reduction in symptoms and 67% no longer qualifying for a PTSD diagnosis (117). The second phase 3 trial is ongoing (118).
With mounting evidence of potential therapeutic use of these agents, FDA approval of MDMA, psilocybin, and ketamine can pave the way for greater exploration and application of psychedelics as therapy for SUDs, including opioid use. Existing evidence on psychedelics on SUDs are anecdotally reported reduction in substance use and small clinical cases or trials (119). Previous open label studies on psilocybin have shown improved abstinence in cigarette and alcohol use (120–122), and a meta-analysis on ketamine’s effect on substance use showed reduced craving and increased abstinence (123). Multiple open-label as well as randomized clinical trials are investigating psilocybin, ketamine, and MDMA-assisted treatment for patients who also have opioid dependence (124–130). Other psychedelic agents, such as LSD, ibogaine, kratom, and mescaline are also of interest as a potential therapeutic for OUD, for their role in reducing craving and substance use (104, 131–140).
Potential neuroimmune modulatory approaches to treating OUD
Changes to brain’s synaptic plasticity via neuroimmune modulation seen in addiction suggest the role of agents that can disrupt and/or mitigate the changes from substance use and addiction as potential therapeutics (141, 142). Existing medications may be applicable to OUD and substance use treatment in this manner, by modulating or reversing synaptic plasticity. For example, N-Acetylcysteine, an antioxidant medication with multiple clinical applications, has shown to reverse cocaine-induced metaplasticity in in rats (143), and ceftriaxone, a third generation cephalosporine antibiotic, has shown to downregulate glutamate transporter 1 (EEAT2) and reduce drug seeking behavior (144, 145). Similarly, spironolactone, a mineralocorticoid receptor antagonist, has been shown to reduce alcohol consumption in both mice and humans, but to a greater degree in humans (146). Novel immune-modulating agents can also be developed to target known signaling pathways involved in addiction and OUD, such as TLR4, a transmembrane protein that plays a role in rewarding effects of substances, leading to reinforcement of use (147–149).
Other neuroimmune modulatory agents are of interest, including biologic agents, such as antibodies, and vaccines that block the effect of substances of abuse (150–154), but low immunogenicity remains a major challenge to being effective in humans. Overall, much more evidence is needed to develop novel neuroimmunotherapeutics as effective treatments for SUDs. However, the potential benefit of the proposed approaches is that they may modulate or even reverse the lasting damages substance use imposes on the brain.
Summary
The nation has had a series of drug overdose epidemics, starting with prescription opioids, moving to injectable heroin and then fentanyl. Addiction policy experts have suggested a number of policy changes that increase access and reduce stigma along with many harm reduction strategies that have been enthusiastically adopted. Despite this, the actual effects on OUD & drug overdose rates have been difficult to demonstrate.
The efficacy of OUD treatments is limited by poor adherence and it is unclear if recovery to premorbid levels is even possible. Comorbid psychiatric, addictive, or medical disorders often contribute to recidivism. While expanding access to treatment and adopting harm reduction approaches are important in saving lives, to reverse the concerning trends in OUD, there must also be novel treatments that are more durable, non-addicting, safe, and effective. Promising potential treatments include neuromodulating modalities such as TMS and DBS, which target different areas of the neural circuitry involved in addiction. Some of these modalities are already FDA-approved for other neuropsychiatric conditions and have evidence of effectiveness in reducing substance use, with several clinical trials in progress. In addition to neuromodulation, psychedelics has been gaining much interest in potential for use in various SUD, with mounting evidence for use of psychedelics in psychiatric conditions. If the FDA approves psilocybin and MDMA after successful phase 3 trials, there will be reduced barriers to investigate applications of psychedelics despite their current classification as Schedule I substances. Like psychedelics, but with less evidence, are neuroimmune modulating approaches to treating addiction. Without new inventions for pain treatment, new treatments for OUD and SUD which might offer the hope of a re-setting of the brain to pre-use functionality and cures we will not make the kind of progress that we need to reverse this crisis.
Conclusion
By using agents that target pathways that lead to changes in synaptic plasticity seen in addiction, this approach can prevent addiction and/or reverse damages caused by addiction. All of these proposed approaches to treating OUD are at various stages in investigation and development. However, the potential benefits of these approaches are their ability to target structural changes that occur in the brain in addiction and treat comorbid conditions, such as other addictions and mood disorders. If successful, they will shift the paradigm of OUD treatment away from the opioid receptor and have the potential to cure, not just manage, OUD.
Statements
Author contributions
YL: Writing – original draft, Writing – review & editing. MG: Writing – original draft, Writing – review & editing. KB: Writing – original draft, Writing – review & editing. PT: Writing – original draft, Writing – review & editing. CH: Writing – original draft, Writing – review & editing. BF: Writing – original draft, Writing – review & editing.
Funding
The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1.
GoldMSBaronDBowirratABlumK. Neurological correlates of brain reward circuitry linked to opioid use disorder (OUD): do homo sapiens acquire or have a reward deficiency syndrome?J Neurol Sci. (2020) 418:117137. doi: 10.1016/j.jns.2020.117137
2.
GoldMSCadetJLBaronDBadgaiyanRDBlumK. Calvin klein (CK) designer cocktail, new “speedball” is the “grimm reaper”: brain dopaminergic surge a potential death sentence. J Syst Integr Neurosci. (2020) 7. doi: 10.15761/jsin.1000227
3.
GoldMS. The role of alcohol, drugs, and deaths of despair in the U.S.'s falling life expectancy. Mo Med. (2020) 117:99–01. PMID:
4.
HillKPGoldMSNemeroffCBMcDonaldWGrzendaAWidgeAet al. Risks and benefits of Cannabis and cannabinoids in psychiatry. Am J Psychiatr. (2022) 179:98–09. doi: 10.1176/appi.ajp.2021.21030320
5.
OesterleTSThusiusNJRummansTAGoldMS. Medication-assisted treatment for opioid-use disorder. Mayo Clin Proc. (2019) 94:2072–86. doi: 10.1016/j.mayocp.2019.03.029
6.
World Drug Report (2021). Available at: https://www.unodc.org/unodc/en/data-and-analysis/wdr2021.html.
7.
AhmadFBCisewskiJARossenLMSuttonP. Provisional drug overdose death counts. National Center for Health Statistics.
8.
SlavovaSRockPBushHMQuesinberryDWalshSL. Signal of increased opioid overdose during COVID-19 from emergency medical services data. Drug Alcohol Depend. (2020) 214:108176. doi: 10.1016/j.drugalcdep.2020.108176
9.
AlexanderGCStollerKBHaffajeeRLSalonerB. An epidemic in the midst of a pandemic: opioid use disorder and COVID-19. Ann Intern Med. (2020) 173:57–8. doi: 10.7326/M20-1141
10.
WangQQKaelberDCXuRVolkowND. COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States. Mol Psychiatry. (2021) 26:30–9. doi: 10.1038/s41380-020-00880-7
11.
KhatriUGPerroneJ. Opioid use disorder and COVID-19: crashing of the crises. J Addict Med. (2020) 14:e6–7. doi: 10.1097/ADM.0000000000000684
12.
GoldMSDeaths, despair tied to drug dependence are accelerating amid COVID-19. (2020). Available at: https://www.mdedge.com/psychiatry/article/227019/coronavirus-updates/deaths-despair-tied-drug-dependence-are-accelerating.
13.
KariisaMSchollLWilsonNSethPHootsB. Drug overdose deaths involving cocaine and psychostimulants with abuse potential - United States, 2003-2017. MMWR Morb Mortal Wkly Rep. (2019) 68:388–95. doi: 10.15585/mmwr.mm6817a3
14.
KhatriUGVinerKPerroneJ. Lethal fentanyl and cocaine intoxication. N Engl J Med. (2018) 379:1782. doi: 10.1056/NEJMc1809521
15.
ElmarasiMGarcia-VassalloGCampbellSFuehrleinB. Brief report: rates of fentanyl use among psychiatric emergency room patients. Am J Addict. (2021) 30:92–5. doi: 10.1111/ajad.13087
16.
LaRueLTwillmanRKDawsonEWhitleyPFrascoMAHuskeyAet al. Rate of fentanyl positivity among urine drug test results positive for cocaine or methamphetamine. JAMA Netw Open. (2019) 2:e192851. doi: 10.1001/jamanetworkopen.2019.2851
17.
PittALHumphreysKBrandeauML. Modeling health benefits and harms of public policy responses to the US opioid epidemic. Am J Public Health. (2018) 108:1394–00. doi: 10.2105/AJPH.2018.304590
18.
GoldMS. Naloxone or Narcan: Life-saving Wonder Drug (2020).
19.
PetersonCLiMXuLMikoszCALuoF. Assessment of annual cost of substance use disorder in US hospitals. JAMA Netw Open. (2021) 4:e210242. doi: 10.1001/jamanetworkopen.2021.0242
20.
StrangJVolkowNDDegenhardtLHickmanMJohnsonKKoobGFet al. Opioid use disorder. Nat Rev Dis Primers. (2020) 6:3. doi: 10.1038/s41572-019-0137-5
21.
TsaiPJKeeleyRJCarmackSAVendruscoloJCMLuHGuHet al. Converging structural and functional evidence for a rat salience network. Biol Psychiatry. (2020) 88:867–78. doi: 10.1016/j.biopsych.2020.06.023
22.
MannB Drug overdose deaths spiked to 88,000 during the pandemic, White house says. (2021). Available at:https://www.npr.org/transcripts/983414684.
23.
ConneryHSWeissRD. Discontinuing buprenorphine treatment of opioid use disorder: what do we (not) know?Am J Psychiatry. (2020) 177:104–6. doi: 10.1176/appi.ajp.2019.19121245
24.
BellJStrangJ. Medication treatment of opioid use disorder. Biol Psychiatry. (2020) 87:82–8. doi: 10.1016/j.biopsych.2019.06.020
25.
NunesEVLevinFRReillyMPel-BasselN. Medication treatment for opioid use disorder in the age of COVID-19: can new regulations modify the opioid cascade?J Subst Abus Treat. (2021) 122:108196. doi: 10.1016/j.jsat.2020.108196
26.
SrivastavaABGoldMS. Naltrexone: a history and future directions. Cerebrum. (2018) 1–14.
27.
LarochelleMRBernsonDLandTStopkaTJWangNXuanZet al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study. Ann Intern Med. (2018) 169:137–45. doi: 10.7326/M17-3107
28.
BruijnzeelAWMarcinkiewczCIsaacSBoothMMDennisDMGoldMS. The effects of buprenorphine on fentanyl withdrawal in rats. Psychopharmacology. (2007) 191:931–41. doi: 10.1007/s00213-006-0670-2
29.
WolfPSGoldM. Treatment resistant opioid use disorder (TROUD): definition, rationale, and recommendations. J Neurol Sci. (2020) 411:116718. doi: 10.1016/j.jns.2020.116718
30.
LeeJDNunesEVNovoPBachrachKBaileyGLBhattSet al. Comparative effectiveness of XR-NTX versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet. (2018) 391:309–18. doi: 10.1016/S0140-6736(17)32812-X
31.
BlumKLottLBaronDSmithDBadgaiyanRGoldM. Improving naltrexone compliance and outcomes with putative pro- dopamine regulator KB220, compared to treatment as usual. J Syst Integr Neurosci. (2020) 6:7. doi: 10.15761/JSIN.1000229
32.
DownsBWBlumKBaronDBowirratALottLBrewerRet al. Death by opioids: are there non-addictive scientific solutions?J Syst Integr Neurosci. (2019) 5:5. doi: 10.15761/JSIN.1000211
33.
DennenACBlumKBravermanREBowirratAGoldMElmanI. How to combat the global opioid crisis. CPQ Neurol Psychol. (2023) 5 [Online ahaed of print].
34.
ChenQLarochelleMRWeaverD. Prevention of prescription opioid misuse and projected overdose deaths in the United States. Substance Use Addict. (2019) 2:1–12. doi: 10.1001/jamanetworkopen.2018.7621
35.
WilliamsARSamplesHCrystalSOlfsonM. Acute care, prescription opioid use, and overdose following discontinuation of long-term buprenorphine treatment for opioid use disorder. Am J Psychiatry. (2020) 177:117–24. doi: 10.1176/appi.ajp.2019.19060612
36.
HillEHanDDumouchelPDehakNQuatieriTMoehsCet al. Long term suboxone™ emotional reactivity as measured by automatic detection in speech. PLoS One. (2013) 8:e69043. doi: 10.1371/journal.pone.0069043
37.
FairleyMHumphreysKJoyceVRBounthavongMTraftonJCombsAet al. Cost-effectiveness of treatments for opioid use disorder. JAMA Psychiatry. (2021) 78:767–7. doi: 10.1001/jamapsychiatry.2021.0247
38.
XuYWangSChenLShaoZZhangMLiuSet al. Reduced midbrain functional connectivity and recovery in abstinent heroin users. J Psychiatr Res. (2021) 144:168–76. doi: 10.1016/j.jpsychires.2021.10.011
39.
BlumKLiuYWangWWangYZhangYOscar-BermanMet al. rsfMRI effects of KB220Z™ on neural pathways in reward circuitry of abstinent genotyped heroin addicts. Postgrad Med. (2015) 127:232–41. doi: 10.1080/00325481.2015.994879
40.
SwensonSBlumKMcLaughlinTGoldMSThanosPK. The therapeutic potential of exercise for neuropsychiatric diseases: a review. J Neurol Sci. (2020) 412:116763. doi: 10.1016/j.jns.2020.116763
41.
BlumKThompsonBDemotrovicsZFeminoJGiordanoJOscar-BermanMet al. The molecular neurobiology of twelve steps program & fellowship: connecting the dots for recovery. J Reward Defic Syndr. (2015) 1:46–4. doi: 10.17756/jrds.2015-008
42.
McLellanATKoobGFVolkowND. Preaddiction-a missing concept for treating substance use disorders. JAMA Psychiatry. (2022) 79:749–51. doi: 10.1001/jamapsychiatry.2022.1652
43.
BlumKHanDBowirratADownsBWBagchiDThanosPKet al. Genetic addiction risk and psychological profiling analyses for "Preaddiction". Severity Index J Pers Med. (2022) 12:1–22. doi: 10.3390/jpm12111772
44.
O'DonnellJKGladdenRMSethP. Trends in deaths involving heroin and synthetic opioids excluding methadone, and law enforcement drug product reports, by census region - United States, 2006-2015. MMWR Morb Mortal Wkly Rep. (2017) 66:897–03. doi: 10.15585/mmwr.mm6634a2
45.
RenardJRosenLGLoureiroMde OliveiraCSchmidSRushlowWJet al. Adolescent cannabinoid exposure induces a persistent sub-cortical hyper-dopaminergic state and associated molecular adaptations in the prefrontal cortex. Cereb Cortex. (2017) 27:1297–10. doi: 10.1093/cercor/bhv335
46.
EdwardsDRoyBoyettBBadgaiyanRDThanosPKBaronDet al. Addiction by any other name is still addiction: embracing molecular neurogenetic/epigenetic basis of reward deficiency. J Addict Sci. (2020) 6:1–4. doi: 10.17756/jas.2020-043
47.
Gondré-LewisMCBasseyRBlumK. Pre-clinical models of reward deficiency syndrome: a behavioral octopus. Neurosci Biobehav Rev. (2020) 115:164–88. doi: 10.1016/j.neubiorev.2020.04.021
48.
MauroPMGutkindSAnnunziatoEMSamplesH. Use of medication for opioid use disorder among US adolescents and adults with need for opioid treatment, 2019. JAMA Netw Open. (2022) 5:e223821. doi: 10.1001/jamanetworkopen.2022.3821
49.
TreitlerPCBowdenCFLloydJEnichMNyakuANCrystalS. Perspectives of opioid use disorder treatment providers during COVID-19: adapting to flexibilities and sustaining reforms. J Subst Abus Treat. (2022) 132:108514. doi: 10.1016/j.jsat.2021.108514
50.
OlsenYFitzgeraldRMWakemanSE. Overcoming barriers to treatment of opioid use disorder. JAMA. (2021) 325:1149–50. doi: 10.1001/jama.2021.1741
51.
WeimerMBWakemanSESaitzR. Removing one barrier to opioid use disorder treatment: is it enough?JAMA. (2021) 325:1147–8. doi: 10.1001/jama.2021.0958
52.
HawkKHoppeJKetchamELaPietraAMoulinANelsonLet al. Consensus recommendations on the treatment of opioid use disorder in the emergency department. Ann Emerg Med. (2021) 78:434–42. doi: 10.1016/j.annemergmed.2021.04.023
53.
HerringAAVosooghiAALuftigJAndersonESZhaoXDziuraJet al. High-dose buprenorphine induction in the emergency Department for Treatment of opioid use disorder. JAMA Netw Open. (2021) 4:e2117128. doi: 10.1001/jamanetworkopen.2021.17128
54.
BlumKJacobsWModestinoEJDiNubileNBaronDMcLaughlinTet al. Insurance companies fighting the peer review empire without any validity: the case for addiction and pain modalities in the face of an American drug epidemic. SEJ Surg Pain. (2018) 1:1–11. PMID:
55.
KrawczykNet al. Has the treatment gap for opioid use disorder narrowed in the U.S.?: a yearly assessment from 2010 to 2019. Int J Drug Policy. (2022) 110:103786
56.
TaylorJLJohnsonSCruzRGrayJRSchiffDBagleySM. Integrating harm reduction into outpatient opioid use disorder treatment settings: harm reduction in outpatient addiction treatment. J Gen Intern Med. (2021) 36:3810–9. doi: 10.1007/s11606-021-06904-4
57.
DackisCAGoldMS. New concepts in cocaine addiction: the dopamine depletion hypothesis. Neurosci Biobehav Rev. (1985) 9:469–77. doi: 10.1016/0149-7634(85)90022-3
58.
BlumKBowirratAGomezLLDownsBWBagchiDBarhDet al. Why haven't we solved the addiction crisis?J Neurol Sci. (2022) 442:120404. doi: 10.1016/j.jns.2022.120404
59.
FeboMBlumKBadgaiyanRDBaronDThanosPKColon-PerezLMet al. Dopamine homeostasis: brain functional connectivity in reward deficiency syndrome. Front Biosci. (2017) 22:669–91. doi: 10.2741/4509
60.
CheronJKerchove d'ExaerdeA. Drug addiction: from bench to bedside. Transl Psychiatry. (2021) 11:424. doi: 10.1038/s41398-021-01542-0
61.
KoobGFVolkowND. Neurobiology of addiction: a neurocircuitry analysis. Lancet Psychiatry. (2016) 3:760–73. doi: 10.1016/S2215-0366(16)00104-8
62.
LuigjesJSegraveRde JoodeNFigeeMDenysD. Efficacy of invasive and non-invasive brain modulation interventions for addiction. Neuropsychol Rev. (2019) 29:116–38. doi: 10.1007/s11065-018-9393-5
63.
WangWZhuYWangLMuLLZhuLDingDet al. High-frequency repetitive transcranial magnetic stimulation of the left dorsolateral prefrontal cortex reduces drug craving and improves decision-making ability in methamphetamine use disorder. Psychiatry Res. (2022) 317:114904. doi: 10.1016/j.psychres.2022.114904
64.
LiXHartwellKJOwensMLeMattyTBorckardtJJHanlonCAet al. Repetitive transcranial magnetic stimulation of the dorsolateral prefrontal cortex reduces nicotine cue craving. Biol Psychiatry. (2013) 73:714–20. doi: 10.1016/j.biopsych.2013.01.003
65.
EkhtiariHTavakoliHAddoloratoGBaekenCBonciACampanellaSet al. Transcranial electrical and magnetic stimulation (tES and TMS) for addiction medicine: a consensus paper on the present state of the science and the road ahead. Neurosci Biobehav Rev. (2019) 104:118–40. doi: 10.1016/j.neubiorev.2019.06.007
66.
Dinur-KleinLDannonPHadarARosenbergORothYKotlerMet al. Smoking cessation induced by deep repetitive transcranial magnetic stimulation of the prefrontal and insular cortices: a prospective, randomized controlled trial. Biol Psychiatry. (2014) 76:742–9. doi: 10.1016/j.biopsych.2014.05.020
67.
AddoloratoGAntonelliMCocciolilloFVassalloGATarliCSestitoLet al. Deep transcranial magnetic stimulation of the dorsolateral prefrontal cortex in alcohol use disorder patients: effects on dopamine transporter availability and alcohol intake. Eur Neuropsychopharmacol. (2017) 27:450–61. doi: 10.1016/j.euroneuro.2017.03.008
68.
PrikrylRUstohalLKucerovaHPKasparekTJarkovskyJHublovaVet al. Repetitive transcranial magnetic stimulation reduces cigarette consumption in schizophrenia patients. Prog Neuro-Psychopharmacol Biol Psychiatry. (2014) 49:30–5. doi: 10.1016/j.pnpbp.2013.10.019
69.
TerraneoALeggioLSaladiniMErmaniMBonciAGallimbertiL. Transcranial magnetic stimulation of dorsolateral prefrontal cortex reduces cocaine use: a pilot study. Eur Neuropsychopharmacol. (2016) 26:37–44. doi: 10.1016/j.euroneuro.2015.11.011
70.
LiuXZhaoXLiuTLiuQTangLZhangHet al. The effects of repetitive transcranial magnetic stimulation on cue-induced craving in male patients with heroin use disorder. EBioMedicine. (2020) 56:102809. doi: 10.1016/j.ebiom.2020.102809
71.
GayACabeJde ChazeronILambertCDefourMBhoowabulVet al. Repetitive transcranial magnetic stimulation (rTMS) as a promising treatment for craving in stimulant drugs and Behavioral addiction: a Meta-analysis. J Clin Med. (2022) 11:1–27. doi: 10.3390/jcm11030624
72.
SahlemG (2023). Accelerated intermittent Theta-burst stimulation for opiate use disorder. Available at: https://clinicaltrials.gov/ct2/show/NCT03804619?term=TMS&cond=Opioid+Use&draw=3&rank=18.
73.
LeeH (2022). Repetitive transcranial magnetic stimulation to reduce heroin cravings U.S. National Library of Medicine. Available at: https://clinicaltrials.gov/ct2/show/NCT05074524?term=TMS&cond=Opioid+Use&draw=3&rank=14.
74.
HanlonC (2023). H-coil TMS to reduce pain: a pilot study evaluating relative efficacy of the H1 vs H7 coil. Available at: https://clinicaltrials.gov/ct2/show/NCT04203199?term=TMS&cond=Opioid+Use&draw=3&rank=13.
75.
VoineskosD (2022). rTMS for suicidality in opioid use disorder. Available at: https://clinicaltrials.gov/ct2/show/NCT04785456?term=TMS&cond=Opioid+Use&draw=3&rank=11.
76.
GreenwaldM (2023). rTMS, stress and opioid use disorder (TOTS) Available at: https://clinicaltrials.gov/ct2/show/NCT04231708?term=TMS&cond=Opioid+Use&draw=2&rank=8.
77.
GreenwaldM (2023). Effects of pharmacological stress and rTMS on executive function in opioid use Disorde. Available at: https://clinicaltrials.gov/ct2/show/NCT04231708?term=TMS&cond=Opioid+Use&draw=2&rank=8.
78.
RushC (2023). Adjunctive transcranial stimulation to reduce impulsivity in opiate use disorder. Available at: https://clinicaltrials.gov/ct2/show/NCT05049460?term=TMS&cond=Opioid+Use&draw=2&rank=7
79.
WangT-Y (2020). Repetitive transcranial magnetic stimulation in patients with opioid use disorders. Available at: https://clinicaltrials.gov/ct2/show/NCT03229642?term=TMS&cond=Opioid+Use&draw=2&rank=6.
80.
HarounA (2022). The role of repetitive trans cranial-magnetic stimulation in craving reduction among opioid use disorder patients. Available at: https://clinicaltrials.gov/ct2/show/NCT04691167?term=TMS&cond=Opioid+Use&draw=2&rank=5
81.
MahoneyJ (2023). An open-label trial of repetitive transcranial magnetic stimulation for opioid use disorder. Available at: https://clinicaltrials.gov/ct2/show/NCT04157062?term=TMS&cond=Opioid+Use&draw=2&rank=4.
82.
BiernackiK (2023). Using combined EEG and non-invasive brain stimulation to examine and improve reward functioning in opioid use disorder. Available at: https://clinicaltrials.gov/ct2/show/NCT04432493?term=TMS&cond=Opioid+Use&draw=2&rank=3
83.
Mcrae-ClarkAL (2022). Transcranial magnetic stimulation (rTMS) as a tool to decrease pain and improve functioning (TMS). Available at: https://clinicaltrials.gov/ct2/show/NCT03821337?term=TMS&cond=Opioid+Use&draw=2&rank=2.
84.
SteeleVRMaxwellAM. Treating cocaine and opioid use disorder with transcranial magnetic stimulation: a path forward. Pharmacol Biochem Behav. (2021) 209:173240. doi: 10.1016/j.pbb.2021.173240
85.
TaghvaASilvetzRRingAKimKYAMurphyKTLiuCYet al. Magnetic resonance therapy improves clinical phenotype and EEG alpha power in posttraumatic stress disorder. Trauma Mon. (2015) 20:e27360. doi: 10.5812/traumamon.27360
86.
HassanOPhanSWiecksNJoaquinCBondarenkoV. Outcomes of deep brain stimulation surgery for substance use disorder: a systematic review. Neurosurg Rev. (2021) 44:1967–76. doi: 10.1007/s10143-020-01415-y
87.
BrownJ (2023). Temporal interference neurostimulation and addiction. Available at: https://clinicaltrials.gov/ct2/show/NCT04432064?term=DBS&cond=Addiction&draw=2&rank=10.
88.
SunB (2020). Deep brain stimulation of the bilateral nucleus Accumbens for patients with methadone maintenance treatment. Available at: https://clinicaltrials.gov/ct2/show/NCT03952455?term=DBS&cond=Addiction&draw=2&rank=7
89.
LuL (2018). Deep brain stimulation of nucleus Accumbens for opioid relapse prevention. Available at: https://clinicaltrials.gov/ct2/show/NCT03424616?term=DBS&cond=Addiction&draw=2&rank=6
90.
LumingL (2016). PINS stimulator system for deep brain stimulation of the nucleus Accumbens to treat severe opioid addiction. Available at: https://clinicaltrials.gov/ct2/show/NCT02282072?term=DBS&cond=Addiction&draw=2&rank=5
91.
KuhnVV. (2016). Deep brain stimulation of the nucleus Accumbens as a novel treatment in severe opioid addiction (NASA). Available at: https://clinicaltrials.gov/ct2/show/NCT01245075?term=DBS&cond=Addiction&draw=2&rank=4
92.
TomyczN (2023). Deep brain stimulation effects in patients with opioid use disorder. Available at: https://clinicaltrials.gov/ct2/show/NCT04354077?term=DBS&cond=Addiction&draw=3&rank=13.
93.
GaoG-D (2016). Brain electrophysiological study(EEG/ERP) on opiate addicts treating by bilateral NAc/ALIC deep brain stimulation. Available at: https://clinicaltrials.gov/ct2/show/NCT02594306?term=DBS&cond=Addiction&draw=3&rank=15.
94.
GaoG-D (2014). Deep brain stimulation of nucleus Accumbens to prevent opiate relapse. Available at: https://clinicaltrials.gov/ct2/show/NCT01274988?term=DBS&cond=Addiction&draw=2&rank=8
95.
EliasWJLipsmanNOndoWGGhanouniPKimYGLeeWet al. A randomized trial of focused ultrasound thalamotomy for essential tremor. N Engl J Med. (2016) 375:730–9. doi: 10.1056/NEJMoa1600159
96.
BondAEShahBBHussDSDallapiazzaRFWarrenAHarrisonMBet al. Safety and efficacy of focused ultrasound thalamotomy for patients with medication-refractory, tremor-dominant Parkinson disease: a randomized clinical trial. JAMA Neurol. (2017) 74:1412–8. doi: 10.1001/jamaneurol.2017.3098
97.
RazzaLBPalumboPMoffaAHCarvalhoAFSolmiMLooCKet al. A systematic review and meta-analysis on the effects of transcranial direct current stimulation in depressive episodes. Depress Anxiety. (2020) 37:594–08. doi: 10.1002/da.23004
98.
ThairHHollowayALNewportRSmithAD. Transcranial direct current stimulation (tDCS): a Beginner's guide for design and implementation. Front Neurosci. (2017) 11:641. doi: 10.3389/fnins.2017.00641
99.
StaggCJNitscheMA. Physiological basis of transcranial direct current stimulation. Neuroscientist. (2011) 17:37–53. doi: 10.1177/1073858410386614
100.
BrunoniARNitscheMABologniniNBiksonMWagnerTet al. Clinical research with transcranial direct current stimulation (tDCS): challenges and future directions. Brain Stimul. (2012) 5:175–95. doi: 10.1016/j.brs.2011.03.002
101.
NitscheMACohenLGWassermannEMPrioriALangNAntalAet al. Transcranial direct current stimulation: state of the art 2008. Brain Stimul. (2008) 1:206–23. doi: 10.1016/j.brs.2008.06.004
102.
InSightec. (2023). Exablate for LIFU neuromodulation in patients with opioid use disorder (OUD). Available at: https://clinicaltrials.gov/ct2/show/NCT04197921?term=focused+ultrasound&cond=opioid&draw=2&rank=1.
103.
NuttDCarhart-HarrisR. The current status of psychedelics in psychiatry. JAMA Psychiatry. (2021) 78:121–2. doi: 10.1001/jamapsychiatry.2020.2171
104.
NicholsDJohnsonMNicholsC. Psychedelics as medicines: an emerging new paradigm. Clin Pharmacol Therap. (2017) 101:209–19. doi: 10.1002/cpt.557
105.
AbdallahCGKrystalJH. Ketamine and rapid acting antidepressants: are we ready to cure, rather than treat depression?Behav Brain Res. (2020) 390:112628. doi: 10.1016/j.bbr.2020.112628
106.
FantegrossiWEMurnaneKSReissigCJ. The behavioral pharmacology of hallucinogens. Biochem Pharmacol. (2008) 75:17–33. doi: 10.1016/j.bcp.2007.07.018
107.
RodriguesLSRossiGNRochaJMOsórioFBousoJCHallakJECet al. Effects of ayahuasca and its alkaloids on substance use disorders: an updated (2016-2020) systematic review of preclinical and human studies. Eur Arch Psychiatry Clin Neurosci. (2022) 272:541–56. doi: 10.1007/s00406-021-01267-7
108.
ShaoLXLiaoCGreggIDavoudianPASavaliaNKDelagarzaKet al. Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. Neuron. (2021) 109:2535–2544.e4. doi: 10.1016/j.neuron.2021.06.008
109.
LyCGrebACCameronLPWongJMBarraganEVWilsonPCet al. Psychedelics promote structural and functional neural plasticity. Cell Rep. (2018) 23:3170–82. doi: 10.1016/j.celrep.2018.05.022
110.
DalyEJTrivediMHJanikALiHZhangYLiXet al. Efficacy of Esketamine nasal spray plus Oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry. (2019) 76:893–03. doi: 10.1001/jamapsychiatry.2019.1189
111.
PopovaVDalyEJTrivediMCooperKLaneRLimPet al. Efficacy and safety of flexibly dosed Esketamine nasal spray combined with a newly initiated Oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. Am J Psychiatry. (2019) 176:428–38. doi: 10.1176/appi.ajp.2019.19020172
112.
MarcusDJBruchasMR. Where ketamine and dopamine collide. Elife. (2021) 10:148. doi: 10.7554/eLife.70148
113.
Awakn Awakn announces positive results from phase II a/B clinical trial. Awakn life sciences Corp. (2022).
114.
COMPASS Pathways announces positive topline results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression. (2021). Available at:https://ir.compasspathways.com/news-releases/news-release-details/compass-pathways-announces-positive-topline-results.
115.
FischerS. Psilocybin therapy in advanced Cancer. Available at: https://clinicaltrials.gov/ct2/show/NCT05398484?term=psilocybin&phase=2&draw=2&rank=1.
116.
SmithKWSicignanoDJHernandezAVWhiteCM. MDMA-assisted psychotherapy for treatment of posttraumatic stress disorder: a systematic review with Meta-analysis. J Clin Pharmacol. (2022) 62:463–71. doi: 10.1002/jcph.1995
117.
MitchellJMBogenschutzMLiliensteinAHarrisonCKleimanSParker-GuilbertKet al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med. (2021) 27:1025–33. doi: 10.1038/s41591-021-01336-3
118.
MAPP2 (2023). A multi-site phase 3 study of MDMA-assisted therapy for PTSD (MAPP2) Available at: https://maps.org/mdma/ptsd/mapp2/.
119.
Garcia-RomeuADavisAKErowidEErowidFGriffithsRRJohnsonMW. Persisting reductions in Cannabis, opioid, and stimulant misuse after naturalistic psychedelic use: an online survey. Front Psych. (2019) 10:955.
120.
BogenschutzMPForcehimesAAPommyJAWilcoxCEBarbosaPCRStrassmanRJ. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol. (2015) 29:289–99. doi: 10.1177/0269881114565144
121.
JohnsonMWGarcia-RomeuACosimanoMPGriffithsRR. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol. (2014) 28:983–92. doi: 10.1177/0269881114548296
122.
JohnsonMWGarcia-RomeuAGriffithsRR. Long-term follow-up of psilocybin-facilitated smoking cessation. Am J Drug Alcohol Abuse. (2017) 43:55–60. doi: 10.3109/00952990.2016.1170135
123.
WalshZMollaahmetogluOMRootmanJGolsofSKeelerJMarshBet al. Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review. BJPsych Open. (2021) 8:e19. doi: 10.1192/bjo.2021.1061
124.
KhawajaH (2023). MDMA for co-occurring PTSD and OUD after childbirth. Available at: https://clinicaltrials.gov/ct2/show/NCT05219175?term=psychedelic&cond=opioid&draw=2&rank=1.
125.
GarlandE (2023). Ketamine assisted psychotherapy for opioid use disorder. Available at: https://clinicaltrials.gov/ct2/show/NCT04892251?term=ketamine&cond=opioid+use&draw=2&rank=1
126.
JonesJ (2023). Ketamine for the treatment of opioid use disorder and depression. Available at: https://clinicaltrials.gov/ct2/show/NCT04177706?term=ketamine&cond=opioid+use&draw=2&rank=2.
127.
BelcherA (2023). Ketamine for OUD and comorbid depression (OUDCD). U.S. National Library of Medicine Available at: https://clinicaltrials.gov/ct2/show/NCT05051449?term=ketamine&cond=opioid+use&draw=2&rank=5.
128.
BrownR (2023). Adjunctive effects of psilocybin and buprenorphine. Available at: https://clinicaltrials.gov/ct2/show/NCT04161066?term=psychedelic&cond=opioid&draw=2&rank=4.
129.
JohnsonMW (2023). Psilocybin for opioid use disorder in patients on methadone maintenance with ongoing opioid use. Available at: https://clinicaltrials.gov/ct2/show/NCT05242029?term=psychedelic&cond=opioid&draw=2&rank=3e.
130.
LouwWF (2023). Standardized natural psilocybin-assisted psychotherapy for tapering of opioid medication. Available at: https://clinicaltrials.gov/ct2/show/NCT05585229?term=psychedelic&cond=opioid&draw=2&rank=2.
131.
Palhano-FontesFBarretoDOniasHAndradeKCNovaesMMPessoaJAet al. Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychol Med. (2019) 49:655–63. doi: 10.1017/S0033291718001356
132.
Agin-LiebesGHaasTFLancelottaRUthaugMVRamaekersJGDavisAK. Naturalistic use of mescaline is associated with self-reported psychiatric improvements and enduring positive life changes. ACS Pharmacol Transl Sci. (2021) 4:543–52. doi: 10.1021/acsptsci.1c00018
133.
ThomasGLucasPCaplerNTupperKMartinG. Ayahuasca-assisted therapy for addiction: results from a preliminary observational study in Canada. Curr Drug Abuse Rev. (2013) 6:30–42. doi: 10.2174/15733998113099990003
134.
BogenschutzMPJohnsonMW. Classic hallucinogens in the treatment of addictions. Prog Neuro-Psychopharmacol Biol Psychiatry. (2016) 64:250–8. doi: 10.1016/j.pnpbp.2015.03.002
135.
BrownTKAlperK. Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. Am J Drug Alcohol Abuse. (2018) 44:24–36. doi: 10.1080/00952990.2017.1320802
136.
WilsonCMillarTMatieschynZ. Novel treatment of opioid use disorder using ibogaine and iboga in two adults. J Psychedel Stud. (2020) 4:1–7. doi: 10.1556/2054.2020.00133
137.
MalcolmBJPolancoMBarsugliaJP. Changes in withdrawal and craving scores in participants undergoing opioid detoxification utilizing ibogaine. J Psychoactive Drugs. (2018) 50:256–65. doi: 10.1080/02791072.2018.1447175
138.
MashDCKoveraCAPabloJTyndaleRErvinFRKamletJDet al. Ibogaine in the treatment of heroin withdrawal. Alkaloids Chem Biol. (2001) 56:155–71. doi: 10.1016/S0099-9598(01)56012-5
139.
BrownTK. Ibogaine in the treatment of substance dependence. Curr Drug Abuse Rev. (2013) 6:3–16. doi: 10.2174/15672050113109990001
140.
KrebsTSJohansenP. Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials. J Psychopharmacol. (2012) 26:994–02. doi: 10.1177/0269881112439253
141.
BlancoCVolkowND. Management of opioid use disorder in the USA: present status and future directions. Lancet. (2019) 393:1760–72. doi: 10.1016/S0140-6736(18)33078-2
142.
NambaMDLeyrer-JacksonJMNagyEKOliveMFNeisewanderJL. Neuroimmune mechanisms as novel treatment targets for substance use disorders and associated comorbidities. Front Neurosci. (2021) 15:650785. doi: 10.3389/fnins.2021.650785
143.
MoussawiKPacchioniAMoranMOliveMFGassJTLavinAet al. N-acetylcysteine reverses cocaine-induced metaplasticity. Nat Neurosci. (2009) 12:182–9. doi: 10.1038/nn.2250
144.
KnackstedtLAMelendezRIKalivasPW. Ceftriaxone restores glutamate homeostasis and prevents relapse to cocaine seeking. Biol Psychiatry. (2010) 67:81–4. doi: 10.1016/j.biopsych.2009.07.018
145.
AbulseoudOACamsariUMRubyCLKasasbehAChoiSChoiDS. Attenuation of ethanol withdrawal by ceftriaxone-induced upregulation of glutamate transporter EAAT2. Neuropsychopharmacology. (2014) 39:1674–84. doi: 10.1038/npp.2014.14
146.
FarokhniaMRentschCTChuongVMcGinnMAElvigSKDouglassEAet al. Spironolactone as a potential new pharmacotherapy for alcohol use disorder: convergent evidence from rodent and human studies. Mol Psychiatry. (2022) 27:4642–52. doi: 10.1038/s41380-022-01736-y
147.
BachtellRHutchinsonMWangXRiceKMaierSWatkinsL. Targeting the toll of drug abuse: the translational potential of toll-like receptor 4. CNS Neurol Disord Drug Targets. (2015) 14:692–9. doi: 10.2174/1871527314666150529132503
148.
WangXNorthcuttALCochranTAZhangXFabisiakTJHaasMEet al. Methamphetamine activates toll-like receptor 4 to induce central immune Signaling within the ventral tegmental area and contributes to extracellular dopamine increase in the nucleus Accumbens Shell. ACS Chem Neurosci. (2019) 10:3622–34. doi: 10.1021/acschemneuro.9b00225
149.
HutchinsonMRNorthcuttALHiranitaTWangXLewisSSThomasJet al. Opioid activation of toll-like receptor 4 contributes to drug reinforcement. J Neurosci. (2012) 32:11187–200. doi: 10.1523/JNEUROSCI.0684-12.2012
150.
TruongTTKostenTR. Current status of vaccines for substance use disorders: a brief review of human studies. J Neurol Sci. (2022) 434:120098. doi: 10.1016/j.jns.2021.120098
151.
HaneyMGundersonEWJiangHCollinsEDFoltinRW. Cocaine-specific antibodies blunt the subjective effects of smoked cocaine in humans. Biol Psychiatry. (2010) 67:59–65. doi: 10.1016/j.biopsych.2009.08.031
152.
Ohia-NwokoOKostenTAHaileCN. Animal models and the development of vaccines to treat substance use disorders. Int Rev Neurobiol. (2016) 126:263–91. doi: 10.1016/bs.irn.2016.02.009
153.
XuAKostenTR. Current status of immunotherapies for addiction. Ann N Y Acad Sci. (2021) 1489:3–16. doi: 10.1111/nyas.14329
154.
PravetoniM. Biologics to treat substance use disorders: current status and new directions. Hum Vaccin Immunother. (2016) 12:3005–19. doi: 10.1080/21645515.2016.1212785
Summary
Keywords
opioid-related disorders, public health, therapeutics, electrical stimulation of the brain, hallucinogens, neuroimmunomodulation, pro-dopamine-regulation, homeostasis
Citation
Lee YK, Gold MS, Blum K, Thanos PK, Hanna C and Fuehrlein BS (2024) Opioid use disorder: current trends and potential treatments. Front. Public Health 11:1274719. doi: 10.3389/fpubh.2023.1274719
Received
08 August 2023
Accepted
29 December 2023
Published
25 January 2024
Volume
11 - 2023
Edited by
Wendy Walwyn, University of California, Los Angeles, United States
Reviewed by
Jannie Hugo, University of Pretoria, South Africa
Cheryl Healton, New York University, United States
Updates
Copyright
© 2024 Lee, Gold, Blum, Thanos, Hanna and Fuehrlein.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Brian S. Fuehrlein, brian.fuehrlein@yale.edu
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.